evipedia.ai
← Back

3HAA for Health & Longevity

Evidence Review created on 09/24/2026 using AI4L / Opus 5.5

Also known as: 3-Hydroxyanthranilic Acid, 3-HAA, 3-HANA, 3-OHAA, 3-Hydroxyanthranilate, 2-Amino-3-hydroxybenzoic Acid

Motivation

3-Hydroxyanthranilic acid (3HAA) is a small molecule the body makes when it breaks down tryptophan, an amino acid found in protein-rich foods. It sits on the route that turns tryptophan into a vital cellular energy molecule. It has drawn interest because raising its levels made worms and mice live longer, and because it appears to calm overactive immune responses.

The molecule has a split reputation. Mid-century cancer researchers suspected it of causing bladder tumors, and chemists have long noted that it can either protect cells from oxidative damage or add to it, depending on its surroundings. More recently, human studies found that blood levels fall with age and rise with sustained endurance training, which revived interest in it as a marker and possible lever of healthy aging.

This review examines what is and is not known about 3HAA: the animal and human evidence behind its proposed benefits for lifespan and immune balance, the unresolved safety questions, how people currently try to raise it, and which open questions remain.

Benefits - Risks - Protocol - Conclusion

This section lists research articles and reviews that give a high-level overview of 3HAA and its role in aging, immunity and disease.

None of the six priority expert sources (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published an overview of 3HAA; the only hit was a short members-only research note on FoundMyFitness summarizing one mouse study. The topic is otherwise confined to academic research, so all five items are scientific papers.

Grokipedia

3-Hydroxyanthranilic acid

Summarizes 3HAA’s chemistry, its place in tryptophan breakdown, its dual protective and damaging oxidative behavior, anti-inflammatory and blood-fat effects, worm longevity data, and its chemical-hazard classification.

Examine

No Examine article on 3HAA exists. Examine.com has no entry for 3-hydroxyanthranilic acid under any of its names.

ConsumerLab

No ConsumerLab article on 3HAA exists. ConsumerLab has not tested or reviewed any 3HAA product.

Systematic Reviews

This section lists the systematic reviews and meta-analyses that report on blood or spinal-fluid 3HAA levels in disease.

No systematic review or meta-analysis has evaluated 3HAA taken as a supplement, so neither its claimed benefits nor its principal risks (cancer, bone and immune effects) are represented here; all three papers concern the body’s own 3HAA levels in disease.

Mechanism of Action

3HAA arises from tryptophan along the kynurenine pathway (the body’s main tryptophan breakdown route). Kynureninase (KYNU, the vitamin B6-dependent enzyme that produces 3HAA) forms it; 3-hydroxyanthranilate 3,4-dioxygenase (HAAO, the iron-dependent enzyme that breaks 3HAA down) converts it via quinolinic acid to NAD+ (a core cellular energy molecule).

  • Redox activity: 3HAA neutralizes hydrogen peroxide and traps fat-damaging radicals, blocking ferroptosis (iron-driven cell death from fat oxidation). Its mild oxidant signal activates Nrf2 (a master switch for antioxidant genes) and HO-1 (heme oxygenase-1, a protective antioxidant enzyme) (Dang et al., 2023; Krause et al., 2011; Liu et al., 2023).
  • Immune restraint: It inhibits PDK1 (an enzyme T cells, the immune system’s coordinating cells, need for activation), shutting off NF-κB (a master inflammation switch), and drains glutathione (the main cellular antioxidant) from activated T cells, killing them (Hayashi et al., 2007; Lee et al., 2010).
  • Blood fats: In liver cells it lowers SREBP-2 (a gene regulator that drives cholesterol production) (Berg et al., 2020).
  • Competing view: With copper or iron, 3HAA generates damaging reactive oxygen species; whether it protects or harms depends on dose, acidity and metals (Goldstein et al., 2000).

Pharmacology: No human pharmacokinetic study exists; half-life is unknown, probably short, given rapid HAAO breakdown in liver and kidney. It lacks a selective target but activates AhR (aryl hydrocarbon receptor, a chemical-sensing receptor) (Ramprasath et al., 2026), crosses the blood-brain barrier poorly (Fukui et al., 1991), and no involvement of the liver’s drug-processing cytochrome P450 enzymes is known.

Historical Context & Evolution

3HAA was never developed as a drug or supplement. It was characterized in the mid-twentieth century as an intermediate in the conversion of tryptophan to niacin (vitamin B3), and its original research interest was purely biochemical.

  • Cancer suspicion (1950s–1970s): Pellets containing 3HAA implanted directly into mouse bladders produced tumors (Allen et al., 1957), and bladder and kidney cancer patients excreted more urinary 3HAA (Teulings et al., 1975). Other implantation and bacterial mutation tests were negative (reviewed by Dang et al., 2023), so the question was left unresolved rather than settled.
  • Oxidant concerns (1990s–2000s): Test-tube studies showed it can generate hydrogen peroxide with metals (Goldstein et al., 2000), reinforcing a “toxic metabolite” image.
  • Immune and heart research (2000s–2010s): Researchers found it restrains overactive T cells and, in mice, reduced asthma (Hayashi et al., 2007) and artery plaque (Zhang et al., 2012).
  • Longevity turn (2017–present): George Sutphin’s group (University of Arizona) found that blocking HAAO extended worm lifespan through 3HAA, then reported longer life in small mouse pilots (Dang et al., 2023); a German exercise group linked falling human 3HAA to age (Joisten et al., 2025).

What changed was evidence of context dependence: protective at physiological concentrations, potentially harmful at very high local ones. The research base comes mostly from publicly funded academic laboratories; AstraZeneca scientists co-authored one HAAO-inhibition study (Berg et al., 2020), and no 3HAA manufacturer or trade group was identified among its funders.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no controlled human trial of 3HAA intake exists, so no clinical endpoint or validated surrogate has been measured after taking it.

Medium 🟩 🟩

No benefit reaches Medium: the human data are observational links between the body’s own 3HAA levels and disease, which are indirect evidence for supplementation rather than a trial or cohort of 3HAA intake.

Low 🟩

Protection Against Cognitive Decline

Blood 3HAA is lower in people with Alzheimer’s dementia, according to a meta-analysis pooling four case-control studies (Choe et al., 2026). In worm models, raising 3HAA delayed paralysis caused by toxic protein clumps (Hull et al., 2024). Supplementation has not been tested in people, and 3HAA enters the brain poorly.

Magnitude: Blood 3HAA was lower in Alzheimer’s dementia than in controls by a standardized mean difference (SMD, the group gap in standard-deviation units) of −0.42 (95% confidence interval [CI, the range likely to contain the true value] −0.61 to −0.22).

Preserved Muscle Mass and Strength

In 505 men averaging 85 years, kynurenine-pathway metabolites including 3HAA statistically explained part of the link between inflammation and low muscle mass (Hetherington-Rauth et al., 2024). Mice lacking the Haao gene had stronger grip (Dang et al., 2023). Human data are cross-sectional only.

Magnitude: Kynurenine-pathway metabolites, including 3HAA and its ratios to neighboring metabolites, accounted for 23–92% of the inverse association between inflammatory markers and muscle mass.

Cardiovascular and Blood-Fat Protection ⚠️ Conflicted

In cholesterol-prone mice, raising 3HAA lowered cholesterol, triglycerides and artery plaque (Zhang et al., 2012; Berg et al., 2020). In 2,819 older Norwegians, plasma 3HAA did not predict heart attacks or unstable angina (worsening chest pain) (Eussen et al., 2015). Net reading: human data do not mirror this.

Magnitude: In cholesterol-prone mice, blocking 3HAA breakdown for eight weeks cut aortic-arch plaque area by about 50%, matching injected 3HAA, and lowered total cholesterol and triglycerides; human cohorts show no association with coronary events.

Speculative 🟨

Extended Lifespan

Raising 3HAA extended worm lifespan by about 30%; small pilot studies found longer life in very old male mice fed 3HAA and in female mice lacking Haao (Dang et al., 2023). Evidence is animal-only.

Reduced Chronic Inflammation

3HAA kills activated T cells, blocks NF-κB and suppresses the inflammasome (an inflammation-triggering protein complex) in immune cells (Hayashi et al., 2007; Berg et al., 2020). Evidence is mechanistic and animal-only.

Protection Against Iron-Driven Tissue Injury ⭕️ Not Central to Health & Longevity

3HAA blocked ferroptosis and protected rat lungs from oxygen injury (Ruan et al., 2025); a synthetic relative protected mouse hearts after restored blood flow (Yang et al., 2025). Bears on acute injury care; animal-only.

Better Infection Defense With Age

In aging worms, 3HAA improved immune function and directly killed gram-negative bacteria (a major bacterial group) (Espejo et al., 2024). This is an unreviewed preprint; no mammalian data exist.

Tumor Growth Suppression ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

3HAA slowed mouse liver and oral tumors (Xue et al., 2023; Gan et al., 2025) but aids others against ferroptosis (Liu et al., 2023). Cancer-therapy relevance; animal and cell data only. Net reading: tumor-dependent.

Benefit-Modifying Factors

  • Genetic variants: Rare loss-of-function variants in KYNU or HAAO disrupt NAD+ production and cause birth defects (Shi et al., 2017); common variants that might tune 3HAA levels in adults have not been studied for benefit.
  • Baseline 3HAA and vitamin B6: Blood 3HAA falls with age in adults; people with the lowest levels, or low vitamin B6 (which kynureninase needs to make 3HAA), plausibly have most to gain, though this is untested (Ulvik et al., 2020).
  • Sex: Men have higher blood 3HAA than women (Joisten et al., 2025). In mice, lifelong Haao loss extended life significantly only in females, while dietary 3HAA was tested only in males (Dang et al., 2023).
  • Pre-existing conditions: High cholesterol and chronic inflammatory states are where animal data show the clearest effects; in rheumatic diseases blood 3HAA is not reduced (Mangoni & Zinellu, 2023), so correction of a deficit is unlikely there.
  • Age: The mouse diet study began at 27 months (Dang et al., 2023), roughly equivalent to people in their late seventies, suggesting any benefit may extend to the oldest adults; younger adults already have higher natural levels.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human has taken 3HAA in a controlled trial, so no documented adverse-event data exist.

Medium 🟥 🟥

No risk reaches Medium: the only human data are observational links between the body’s own 3HAA or its breakdown products and disease, not adverse events recorded after intake.

Low 🟥

Bladder Cancer ⚠️ Conflicted

3HAA pellets implanted in mouse bladders caused tumors (Allen et al., 1957), and bladder cancer patients excrete more urinary 3HAA (Teulings et al., 1975). Slower-release pellets and bacterial mutation tests were negative (reviewed by Dang et al., 2023). Net reading: risk appears tied to very high local concentrations.

Magnitude: Tumors arose only after direct bladder implantation of fast-releasing pellets, with estimated urine levels near 1.2 mM, far above those in 3HAA-fed mice; the literature reports no incidence figure for oral intake.

Raised Quinolinic Acid

HAAO turns 3HAA into quinolinic acid, which overstimulates NMDA receptors (brain receptors for the signaling chemical glutamate). In humans, higher quinolinic acid is linked to frailty and death (Al Saedi et al., 2022; Damerell et al., 2025). Whether oral 3HAA raises it is unmeasured.

Magnitude: Among 2,102 colorectal cancer patients, each doubling of circulating quinolinic acid was associated with a 31% higher risk of death (hazard ratio [HR, relative risk over time] 1.31, 95% CI 1.05–1.63).

Speculative 🟨

Oxidative Damage and Cataract

With copper or iron, 3HAA generated hydrogen peroxide and cross-linked eye-lens proteins in test tubes, a proposed cataract mechanism (Goldstein et al., 2000). Evidence is in-vitro only.

Bone Loss ⚠️ Conflicted

3HAA damaged bone-forming stem cells and lowered bone density in mice (Alhamad et al., 2026), yet protected bone in estrogen-deficient rats (Zhu et al., 2024). Evidence is animal-only. Net reading: direction unresolved.

Aortic Aneurysm

In mice, 3HAA activated an artery-wall-degrading enzyme, and blocking its production prevented aortic aneurysm (weakened, bulging aorta) (Wang et al., 2017; Ramprasath et al., 2026). Human aneurysm tissue stains strongly for 3HAA. Evidence is animal-only.

Faster Growth of Existing Tumors

3HAA traps fat-damaging radicals, letting tumor cells escape ferroptosis; the enzyme producing it made cancer cells resistant, and this pathway promoted tumor growth (Liu et al., 2023). Evidence is cell and animal data only.

Immune Suppression

3HAA selectively kills activated T cells (Lee et al., 2010), and 3HAA-fed mice had fewer natural killer cells (infection- and tumor-killing immune cells) (Dang et al., 2023), possibly weakening these defenses. Data are animal-only.

Slowed Growth and Delayed Reproduction

Lacking HAAO slowed early growth in worms and mice and delayed egg-laying in worms (Dang et al., 2023). Relevance to adults is unclear; evidence is animal-only.

Acute Toxicity and Irritation

Chemical-safety classifications list 3HAA as harmful if ingested, inhaled or absorbed through skin, and as a skin, eye and airway irritant. These rest on hazard-labeling data, not human dosing studies.

Risk-Modifying Factors

  • Genetic variants: No common variant is known to change 3HAA risk; rare KYNU or HAAO defects alter pathway balance and would make any response unpredictable.
  • Baseline biomarkers: Pre-existing blood in the urine, low bone density, or high quinolinic acid mark people in whom the bladder, bone or quinolinic-acid concerns would matter most.
  • Sex: Women have lower natural 3HAA and higher osteoporosis risk, so the bone-loss signal may matter more; men carry roughly four times the bladder cancer risk.
  • Pre-existing conditions: Prior bladder or kidney cancer, osteoporosis, immune suppression, copper or iron overload, and reduced kidney clearance of 3HAA each amplify a listed risk.
  • Age: Older adults face higher baseline cancer, cataract and fracture rates, and slower kidney clearance, so the speculative risks carry more weight at the older end of the target range.

Key Interactions & Contraindications

  • Immunosuppressants (tacrolimus, cyclosporine, methotrexate): Avoid; additive suppression of activated T cells may raise infection risk, so people on these drugs are listed below among those who should avoid 3HAA.
  • Statins (cholesterol-lowering drugs such as atorvastatin, rosuvastatin): Monitor; 3HAA lowered cholesterol in mice, so additive lipid lowering is possible. A lipid panel after 8–12 weeks shows the combined effect.
  • Vitamin B6 antagonists (isoniazid, hydralazine, penicillamine): Monitor; these deplete vitamin B6 and reduce kynureninase activity, lowering the body’s own 3HAA production. Vitamin B6 co-supplementation is standard with isoniazid.
  • Ferroptosis-inducing cancer drugs (sorafenib, cisplatin): Avoid; 3HAA’s radical-trapping action could blunt ferroptotic killing of tumor cells, though in mice it strengthened sorafenib against liver cancer (Gan et al., 2021). Active cancer during such treatment is listed below.
  • Iron and copper products (ferrous sulfate, copper-containing multivitamins; over the counter): Caution; these metals switch 3HAA toward generating hydrogen peroxide and damaging proteins (Goldstein et al., 2000). Separating intake by at least 4 hours is a plausible, untested precaution.
  • N-acetylcysteine and glutathione supplements: Monitor; restoring glutathione completely blocked 3HAA-induced death of activated T cells (Lee et al., 2010), which may blunt its anti-inflammatory action while buffering its oxidative stress.
  • Vitamin B6 supplements (pyridoxine, pyridoxal 5’-phosphate): Monitor; additive, since vitamin B6 powers kynureninase and supports the body’s own 3HAA production (Ulvik et al., 2020). Serum 3HAA testing shows the combined effect.
  • Tryptophan supplements (L-tryptophan): Monitor; extra tryptophan feeds the kynurenine pathway and may raise quinolinic acid alongside 3HAA. Checking quinolinic acid after 8–12 weeks detects this.
  • Vitamin C (ascorbic acid): No adverse interaction known; possibly protective, as high-dose ascorbate prevented bladder tumors from implanted 3HAA pellets in mice (Pipkin et al., 1969).
  • Additive lipid-lowering supplements (red yeast rice, berberine, plant sterols): Monitor; combined cholesterol lowering is possible given 3HAA’s lipid effect in mice. A lipid panel after 8–12 weeks shows the combined effect.
  • Additive Nrf2 activators (sulforaphane, curcumin): Monitor; they activate the same antioxidant switch as 3HAA, so effects may add. No combined data exist; introducing one agent at a time clarifies tolerance.
  • NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide, niacin): Monitor; these supply NAD+ downstream of 3HAA, and the Sutphin group proposes complementary effects (Dang et al., 2023), but combinations are untested. No dose change is established.
  • Endurance exercise: Monitor; additive, since 26 weeks of endurance training raised serum 3HAA by 85–134% (Joisten et al., 2025), compounding total exposure. Serum 3HAA testing shows the combined level.

Populations who should avoid 3HAA:

  • Current or prior bladder or kidney cancer, or unexplained microscopic hematuria (blood in the urine, ≥3 red blood cells per high-power field)
  • Active cancer, especially during ferroptosis-inducing treatment
  • Pregnancy, breastfeeding, and people under 18 years, given slowed growth and delayed reproduction with HAAO loss in animals
  • Osteoporosis (bone-density T-score, the number of standard deviations from a healthy young adult’s bone density, ≤ −2.5)
  • Organ transplant recipients, people on immunosuppressants, or lymphocyte counts below 1.0 × 10⁹/L
  • Iron or copper overload, such as hemochromatosis (inherited iron overload; transferrin saturation >45%) or Wilson disease (inherited copper overload)
  • Advanced kidney disease (eGFR, estimated glomerular filtration rate, a measure of kidney filtering, below 30 mL/min/1.73 m²)
  • Known abdominal aortic aneurysm or aortic dilation (diameter ≥3.0 cm)

Risk Mitigation Strategies

  • Exercise route first: Endurance training raised blood 3HAA by 85–134% in middle-aged adults (Joisten et al., 2025), increasing levels while avoiding the bladder, bone and immune risks of unknown oral doses.
  • Lowest effective intake: In aging mice, a diet with 312.5 parts per million (ppm) outperformed a tenfold higher dose (Dang et al., 2023); keeping intake low limits the high local concentrations linked to bladder tumors.
  • Urine screening: Urinalysis for blood at baseline, 4 weeks, 12 weeks, then every 6 months detects early signs of the bladder cancer risk; microscopic hematuria is a reason to stop.
  • Hydration: Drinking 2–3 L of fluid daily dilutes urine 3HAA, lowering the bladder-wall concentration implicated in tumor formation.
  • Vitamin C co-intake: High-dose ascorbate prevented 3HAA-pellet bladder tumors in mice (Pipkin et al., 1969); 500–1,000 mg daily is a low-risk hedge against bladder and oxidative-damage risks, untested in people.
  • Separation from iron and copper: Taking 3HAA at least 4 hours apart from iron or copper supplements reduces the metal-driven hydrogen peroxide generation behind the oxidative damage and cataract concern.
  • Quinolinic acid check: Plasma quinolinic acid at baseline and after 8–12 weeks detects the raised quinolinic acid risk; a sustained rise above one’s own baseline is a reason to reduce or stop.
  • Bone density tracking: A DXA scan (dual-energy X-ray absorptiometry, a low-dose bone density scan) at baseline and after 12 months monitors the bone-loss risk; a decline beyond expected age-related loss is a reason to stop.
  • Aortic screening: A one-time abdominal ultrasound before starting, and avoidance where the aorta measures 3.0 cm or more, addresses the aneurysm signal seen in mice; new abdominal or back pain is a reason to stop.
  • Infection vigilance: A complete blood count (CBC) with differential at baseline and 12 weeks detects immune suppression; pausing 3HAA during active infections avoids weakening T-cell defense.
  • Adults only: Restricting use to adults past growth, as the Sutphin group suggests for late-life use (Dang et al., 2023), avoids the slowed growth and delayed reproduction seen with HAAO loss.
  • Handling precautions: Gloves, eye protection and avoiding dust inhalation when weighing the powder reduce the skin, eye and airway irritation flagged in chemical-safety classifications.

Therapeutic Protocol

  • No established human protocol: No human dosing study exists and no clinician or clinic has published a 3HAA regimen; 3HAA is sold only as a research chemical labeled not for human use.
  • Dietary 3HAA (animal-derived approach): George Sutphin’s group fed aging mice 312.5 or 3,125 ppm 3HAA in chow from 27 months; both lived longer, the lower dose longest, raising serum 3HAA about 3- and 17-fold (Dang et al., 2023).
  • Endurance training (physiological approach): Philipp Zimmer’s group showed that 26 weeks of steady moderate or progressively harder endurance training raised serum 3HAA by 85–134% in middle-aged adults (Joisten et al., 2025).
  • HAAO inhibition (pharmacological approach): Blocking the enzyme that breaks 3HAA down raised the body’s own 3HAA in worms and mice (Dang et al., 2023; Berg et al., 2020); no inhibitor is available for human use.
  • Supporting production: Adequate vitamin B6 keeps kynureninase working; plasma pyridoxal 5’-phosphate (PLP, the active form of vitamin B6) below about 20 nmol/L marks deficiency (Ulvik et al., 2020).
  • Time of day: No study has examined timing; mice received 3HAA continuously through food, so intake with meals most closely mirrors the tested exposure.
  • Half-life: Unknown in humans; rapid breakdown by HAAO in liver and kidney suggests a short half-life, with blood levels probably falling within hours of a dose.
  • Single versus split dosing: Because mouse exposure was continuous and the half-life is presumably short, split doses with meals approximate the tested pattern better than one daily dose; no human comparison exists.
  • Genetic variants: No pharmacogenetic data exist; people with known KYNU or HAAO variants may produce or clear 3HAA unpredictably, making dose response harder to anticipate.
  • Sex: Men have higher natural 3HAA than women; lifelong Haao loss extended life significantly only in female mice, while dietary 3HAA was tested only in males, so dose response may differ by sex.
  • Age: The mouse diet began at an age comparable to people in their late seventies, and the Sutphin group suggests limiting 3HAA elevation to later life because HAAO loss slows early growth (Dang et al., 2023).
  • Baseline biomarkers: Serum 3HAA, quinolinic acid and vitamin B6 measured before starting identify people with low 3HAA, the group most plausibly able to benefit, and provide a reference for change.
  • Pre-existing conditions: Animal benefits were clearest with high cholesterol and chronic inflammation; a history of bladder cancer, osteoporosis or immune suppression shifts the balance against use.

Discontinuation & Cycling

  • Lifelong or short-term: Unknown; mouse benefits came from continuous exposure until death, suggesting any benefit depends on ongoing intake, but no human duration data exist.
  • Withdrawal effects: None reported; the body makes 3HAA constantly, so stopping is expected to return levels to baseline without rebound.
  • Tapering: No tapering protocol exists or appears necessary; abrupt stopping is reasonable if hematuria, bone loss, frequent infections or rising quinolinic acid appear.
  • Cycling: No study has tested cycling; the animal lifespan data came from uninterrupted exposure, so cycling for efficacy has no evidence base.

Sourcing and Quality

  • Research chemical only: 3HAA (Chemical Abstracts Service number 548-93-6) is sold by laboratory suppliers such as Sigma-Aldrich and Cayman Chemical, labeled for research rather than human use; no supplement-grade or pharmaceutical product exists.
  • Purity: A batch certificate of analysis showing at least 98% purity by high-performance liquid chromatography matters, since related metabolites such as anthranilic acid and 3-hydroxykynurenine are plausible contaminants.
  • Metal contamination: Heavy-metal testing, including copper and iron, matters more than usual, because trace metals turn 3HAA into a hydrogen peroxide generator.
  • Stability and storage: 3HAA oxidizes readily and darkens toward red-brown; sealed, dry, cold and dark storage slows this, and discolored material has degraded.
  • Third-party testing: No third-party program (United States Pharmacopeia, NSF International, ConsumerLab) covers 3HAA; independent analytical testing of each batch is the only verification option.

Practical Considerations

  • Time to effect: Unknown in humans; endurance training raised serum 3HAA over 26 weeks, and mouse grip-strength and lifespan effects emerged after weeks to months of continuous intake.
  • Common pitfalls: Confusing 3HAA with 3-hydroxykynurenine or anthranilic acid, assuming it always acts as an antioxidant, combining it with iron or copper supplements, and extrapolating animal doses without urine and blood testing.
  • Regulatory status: 3HAA is not an approved drug and is not marketed as a dietary supplement; suppliers label it not for human use, and chemical-safety data classify it as harmful if ingested.
  • Cost and accessibility: Difficult to access; only laboratory suppliers sell it, typically to institutional buyers, in milligram-to-gram quantities at research-chemical prices.
  • Measuring levels: Serum 3HAA is not a routine clinical test; it requires a research or specialty laboratory offering kynurenine-pathway panels by liquid chromatography–mass spectrometry.

Interaction with Foundational Habits

  • Sleep: None known; no study links 3HAA to sleep. Tryptophan feeds both the kynurenine pathway and melatonin, but 3HAA lies downstream of that branch point and is not expected to divert tryptophan from melatonin. No timing adjustment is indicated.
  • Nutrition: Indirect; dietary tryptophan (protein-rich foods) and vitamin B6 (poultry, fish, potatoes, chickpeas) supply the raw material and enzyme helper for the body’s own 3HAA. Iron- or copper-rich supplements taken with 3HAA may favor its oxidant side; vitamin C–rich foods may counter it.
  • Exercise: Potentiating; 26 weeks of endurance training raised serum 3HAA by 85–134% in middle-aged adults (Joisten et al., 2025), the only tested human lever. Steady moderate and progressively harder training worked similarly; effects on muscle adaptation remain unstudied.
  • Stress management: Indirect; stress hormones and inflammation activate the upstream enzymes that start tryptophan breakdown, shifting pathway balance, but effects on 3HAA itself are unmeasured. Stress-reduction practices are not known to change 3HAA.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes a personal reference and flags people for whom the listed risks matter most. It covers serum 3HAA and quinolinic acid from a specialty kynurenine-pathway panel, urinalysis for blood, vitamin B6 as PLP, a lipid panel with LDL-C (low-density lipoprotein cholesterol, the main artery-clogging cholesterol), high-sensitivity C-reactive protein (hs-CRP, a general inflammation marker), a CBC with differential, eGFR, ferritin and serum copper, and a DXA bone density scan.

Ongoing monitoring follows a cadence of 4 weeks, 12 weeks, then every 6 months. Urinalysis and CBC are repeated at each timepoint; serum 3HAA and quinolinic acid at 12 weeks, then every 6 months; lipids and hs-CRP at 12 weeks; and DXA after 12 months. Because no human target exists, success means a measurable 3HAA rise without new urine blood, falling lymphocytes, rising quinolinic acid or bone loss.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum 3HAA No established target; track change from own baseline Confirms exposure Specialty kynurenine panel; fasting morning draw; pair with quinolinic acid
Plasma quinolinic acid No established target; track change from own baseline Downstream harm signal Same panel as 3HAA; a sustained rise is the concern
Urinalysis (blood) Negative; 0–2 red blood cells per high-power field Bladder safety Conventional cutoff of 3 or more cells defines microscopic hematuria; midstream sample, not during menstruation
Vitamin B6 (PLP) ≥30 nmol/L Supports 3HAA production Conventional deficiency below 20 nmol/L; avoid B6 supplements for 24 hours before testing
LDL-C <100 mg/dL Tracks lipid effect Conventional reference <130 mg/dL; pair with triglycerides (optimal <100 mg/dL, conventional <150 mg/dL); fasting
hs-CRP <1.0 mg/L Inflammation response Conventional <3.0 mg/L; not during acute illness
CBC with differential (lymphocytes) 1.5–3.0 × 10⁹/L Immune suppression Conventional 1.0–4.8 × 10⁹/L; natural killer cells fell in 3HAA-fed mice
eGFR >90 mL/min/1.73 m² Kidney clearance Conventional >60 mL/min/1.73 m²; pair with cystatin C in muscular adults
Ferritin and serum copper Ferritin 50–150 ng/mL; copper 80–120 µg/dL Metal load Conventional ferritin about 30–400 ng/mL (men) and 15–150 ng/mL (women), copper 70–140 µg/dL; high metals favor 3HAA’s oxidant side
DXA bone density T-score above −1.0 Bone-loss signal Conventional: −1.0 to −2.5 is osteopenia (low bone mass), ≤ −2.5 osteoporosis; baseline and 12 months

Qualitative markers:

  • Energy and physical performance, such as grip strength and walking endurance
  • Frequency and duration of infections
  • Urinary symptoms, such as visible blood, urgency or pain
  • Vision changes, such as new glare or cloudiness
  • Attention and mental clarity

Emerging Research

  • No registered human trials: A ClinicalTrials.gov search in September 2026 found no trial giving 3HAA or an HAAO inhibitor to people. A first human dosing and safety study would change the evidence base more than any further animal result.
  • Exercise-raised 3HAA: The first human intervention data show endurance training raising serum 3HAA (Joisten et al., 2025); whether that rise contributes to exercise benefits is untested and could strengthen or weaken the case for supplementation.
  • Attention and gut microbes: Across three cohorts totaling 1,084 adults, plasma 3HAA tracked better attention, especially in obesity, and 3HAA offset diet-induced attention deficits in fruit flies (Castells-Nobau et al., 2026).
  • Neurodegeneration models: 3HAA delayed toxic-protein paralysis in worm models of Alzheimer’s and Huntington’s disease (an inherited brain-degeneration disorder) (Hull et al., 2024), while blood 3HAA is lower in Alzheimer’s dementia (Choe et al., 2026); mammalian brain studies are pending.
  • Cancer direction: 3HAA restrained liver cancer cell growth by rebalancing mitochondria (Liu et al., 2026), yet helps other tumors escape ferroptosis (Liu et al., 2023); tumor-burden data from long-term dosing will be decisive.
  • Bone safety: 3HAA impaired bone-forming cells and cortical bone (the dense outer bone layer) in mice (Alhamad et al., 2026); replication and human bone data could weaken the case substantially.
  • Synthetic analogs: A 3HAA analog blocked ferroptosis about 100-fold more potently and protected mouse hearts after restored blood flow (Yang et al., 2025), suggesting drug development may bypass 3HAA itself.
  • Sweat measurement: 3HAA was detected in the sweat of all 81 adults aged 50–79 and rose with age (Katewongsa et al., 2024), pointing to non-invasive monitoring but contrasting with the age-related decline seen in blood.

Conclusion

3HAA is a natural product of the body’s breakdown of tryptophan, an amino acid in protein foods, on the route that makes a key cellular energy molecule. Interest in it for healthy aging rests almost entirely on animal work: raising it lengthened life in worms and, in small early studies, in mice, and it reduced artery plaque and calmed overactive immune cells in rodents. Human evidence is limited to observations that blood levels fall with age, are lower in Alzheimer’s dementia and rise with sustained endurance training. None of this shows that taking 3HAA improves any human health outcome, and no person has taken it in a proper trial.

The risks are just as uncertain. Old experiments tied very high concentrations inside the bladder to tumors, some cancers use 3HAA to shield themselves, and recent mouse work links it to weaker bone and aorta. Its breakdown product, tied to frailty and death in studies of blood levels, raises another open question. Whether 3HAA protects or damages cells depends on the amount, acidity and the presence of iron or copper.

For health-focused adults prepared to look beyond conventional options, 3HAA sits at an early, mostly animal-based stage and is obtainable only as a laboratory chemical. The one tested human way of raising it is sustained endurance exercise. The research comes mostly from publicly funded academic groups, with one drug-company collaboration on blocking 3HAA’s breakdown, and the evidence base is small, preliminary and points in more than one direction.

Top - Benefits - Risks - Protocol